• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

    10/28/24 7:00:00 AM ET
    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Industrial Specialties
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ISRG alert in real time by email

    SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner.

    Sonder Capital

    Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered the use of person-generated health data and connected devices in decentralized research and large-scale health programs. Prior to Evidation, Kilpatrick held leadership roles in medical device and molecular diagnostic companies, including multiple roles at Guidant Corporation such as Research Fellow, Director of Research and Technology Development, and Director of New Ventures, prior to its acquisition by Boston Scientific. She is the co-Founder of MedtechWomen and the MedtechVision Conference, held annually in Silicon Valley and currently serves on the Board of Directors at Sleep Number (NASDAQ:SNBR), NextGen Jane, and Sutter Health, one of the largest and most innovative healthcare systems in the US providing care to millions throughout California.

    Kilpatrick's background in medical devices coupled with her expertise in digital health technology will strengthen the Sonder team's ability to navigate and identify future investments in the medtech sector as it rapidly evolves to integrate multi-modal health data and AI.

    "I'm excited to join the Sonder team and be a part of creating what's next in medtech," said Kilpatrick. "There is no doubt that the sector has driven better patient outcomes for decades. But I believe medtech is entering a new era where novel technologies will drive entirely new standards of care and transform both the clinician and patient experience in ways we are just beginning to imagine."

    "We couldn't be more excited to welcome Deb to the Sonder team," said Kate Garrett, Managing Partner of Sonder Capital. "The future of the medtech industry will become a convergence of big data, AI and connected devices, creating unprecedented opportunities to improve healthcare. With a career deeply rooted in all of these areas, Deb brings unparalleled expertise to our team. Beyond that, Deb has been a champion of women leaders in the healthcare sector her entire career, something I and thousands of others have benefitted from. We are thrilled to be working side by side with her."

    About Sonder Capital

    Sonder's team of veteran investors, innovators, founder-operators, and company builders is known not only for their individual achievements, but also for their collective success in creating, funding, and leading private and public companies that have transformed healthcare for millions of patients globally — including Intuitive Surgical (NASDAQ:ISRG), Shockwave Medical (NASDAQ:SWAV), Procept Biorobotics (NASDAQ:PRCT), Auris Health, and Reflexion Medical, among others. Sonder's extensive network of limited partners is global and includes industry leaders, high-net-worth individuals, and leading family offices focused on investing in game-changing healthcare technologies. Sonder Capital was co-founded in 2019 by healthcare luminaries Jay Watkins and Fred Moll, M.D

    Contacts

    Marisa Meehan, Sonder Capital

    marisa@sondercapital.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/deborah-kilpatrick-joins-sonder-capital-as-its-newest-venture-partner-302288301.html

    SOURCE Sonder Capital

    Get the next $ISRG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • Who has been appointed as the new Venture Partner at Sonder Capital?

      Deborah Kilpatrick has joined Sonder Capital as a Venture Partner, bringing extensive experience in healthcare technology and leadership roles in the medtech sector.

    • What was Deborah Kilpatrick's previous role before joining Sonder Capital?

      Kilpatrick was previously the CEO of Evidation Health, where she led efforts in utilizing person-generated health data and connected devices for research and health programs.

    • What is Deborah Kilpatrick's educational background?

      Kilpatrick holds a Ph.D. in mechanical engineering with a focus on bioengineering from Georgia Tech and has been involved in various leadership roles in medical device companies, including Guidant Corporation.

    • Why is Deborah Kilpatrick's addition significant for Sonder Capital?

      Joining Sonder Capital enhances their investment capabilities in the rapidly evolving medtech sector, especially in areas integrating multi-modal health data and AI.

    • What vision did Deborah Kilpatrick express about the future of the medtech sector?

      Kilpatrick emphasized that medtech is entering a new era where innovative technologies will set new standards of care and significantly enhance patient and clinician experiences.

    Recent Analyst Ratings for
    $ISRG
    $PRCT
    $SNBR
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Intuitive Surgical Inc.
    $ISRG
    3/11/2026$590.00Neutral → Buy
    Citigroup
    PROCEPT BioRobotics Corporation
    $PRCT
    3/6/2026$30.00Neutral
    Robert W. Baird
    PROCEPT BioRobotics Corporation
    $PRCT
    2/26/2026Outperform → Perform
    Oppenheimer
    PROCEPT BioRobotics Corporation
    $PRCT
    2/26/2026$20.00Neutral → Underperform
    BofA Securities
    Intuitive Surgical Inc.
    $ISRG
    1/27/2026$660.00Buy
    TD Cowen
    PROCEPT BioRobotics Corporation
    $PRCT
    12/12/2025$62.00Buy
    UBS
    Intuitive Surgical Inc.
    $ISRG
    12/11/2025$635.00Buy → Neutral
    Citigroup
    PROCEPT BioRobotics Corporation
    $PRCT
    12/8/2025$38.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intuitive Surgical upgraded by Citigroup with a new price target

    Citigroup upgraded Intuitive Surgical from Neutral to Buy and set a new price target of $590.00

    3/11/26 8:28:54 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    Robert W. Baird initiated coverage on PROCEPT BioRobotics with a new price target

    Robert W. Baird initiated coverage of PROCEPT BioRobotics with a rating of Neutral and set a new price target of $30.00

    3/6/26 8:35:41 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics downgraded by Oppenheimer

    Oppenheimer downgraded PROCEPT BioRobotics from Outperform to Perform

    2/26/26 7:23:22 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intuitive Announces New Chief Commercial and Marketing Officer Taylor Patton

    SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the promotion of Global Senior Vice President of Intuitive's endoluminal business Taylor Patton to Chief Commercial and Marketing Officer, effective July 1. Patton will join Intuitive's Executive Leadership team and succeed Henry Charlton, who will assume the role of Senior Vice President of Global Business Operations. Charlton will work closely with Patton to support a smooth transition advancing Intuitive's global impact and excellence in support of customers and their work to expand access to mini

    5/28/26 4:30:00 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

    SAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation® therapy versus radical prostatectomy, and FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablation therapy versus active surveillance. The first randomized WATER IV study (WATER IV RP) fully enrolled 280 planned patients and is the only FDA randomized study comparing Aquablation therapy to radical prostatectomy, the established surgical standard of care. Based on current timelines, the Company e

    5/28/26 8:00:00 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Intuitive Announces Innovations to Advance Quintuple Aim

    SUNNYVALE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced several recent and upcoming innovations, including enhancements across da Vinci 5 and its supporting ecosystem, extended‑use Force Feedback instruments, and advancements designed to enhance product and instrument security and reliability. "Intuitive is guided by a commitment to helping our customers achieve the Quintuple Aim: improving patient care and outcomes, optimizing surgeon and care team experience, and expanding access to minimally invasive care while lowering the total cost of care," said In

    5/21/26 9:15:00 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Desai Antal Rohit bought $10,482,943 worth of shares (426,262 units at $24.59) (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/9/26 7:19:42 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Director Moll Frederic H bought $785,138 worth of shares (20,000 units at $39.26), increasing direct ownership by 2% to 863,159 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:18:26 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Interim CFO Ryder Robert P bought $102,160 worth of shares (15,000 units at $6.81) (SEC Form 4)

    4 - Sleep Number Corp (0000827187) (Issuer)

    8/4/25 4:05:05 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & GM da Vinci Platforms & Jeddi Iman sold $2,365,594 worth of shares (5,625 units at $420.55) as part of a pre-agreed trading plan and exercised 5,625 shares at a strike of $77.00 (SEC Form 4)

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    6/2/26 10:08:13 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    Large owner Stadium Capital Management Llc sold $695,052 worth of shares (390,676 units at $1.78) (SEC Form 4)

    4 - Sleep Number Corp (0000827187) (Issuer)

    6/1/26 7:49:06 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    EVP & Chief Mfg and Supply Cha Brosius Mark sold $15,945 worth of shares (36 units at $442.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,523 units (SEC Form 4)

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    5/22/26 8:09:35 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    SEC Filings

    View All

    Sleep Number Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Sleep Number Corp (0000827187) (Filer)

    6/2/26 4:05:17 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    SEC Form SD filed by PROCEPT BioRobotics Corporation

    SD - PROCEPT BioRobotics Corp (0001588978) (Filer)

    6/1/26 5:27:17 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Intuitive Surgical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)

    5/28/26 4:35:49 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    Sleep Number Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    Sleep Number Corporation (NASDAQ:SNBR) today announced that it granted equity awards on March 16, 2026, as a material inducement to the employment of the company's Executive Vice President and Chief Financial Officer, Amy O'Keefe. As previously disclosed, in connection with the appointment of O'Keefe as Executive Vice President and Chief Financial Officer effective December 8, 2025, Sleep Number agreed to grant O'Keefe employment inducement awards on or around March 15, 2026. The equity awards granted on March 16, 2026 pursuant to that agreement consist of: (i) 66,965 shares of common stock underlying a time-vested restricted stock unit award, vesting in three equal installments on each a

    3/16/26 4:00:00 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Sleep Number Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Sleep Number Corporation (NASDAQ:SNBR) today announced that it granted an equity award on December 15, 2025, as a material inducement to the employment of the company's newly-hired Executive Vice President and Chief Financial Officer, Amy O'Keefe. As previously disclosed, in connection with the appointment of O'Keefe as Executive Vice President and Chief Financial Officer effective December 8, 2025, Sleep Number granted O'Keefe an employment inducement award consisting of 69,742 shares in a time-vested restricted stock unit award that vests in three equal installments on each anniversary from the date of grant. The grants are subject to continued employment and the terms of the award agree

    12/15/25 4:01:00 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Financials

    Live finance-specific insights

    View All

    Sleep Number Announces First Quarter 2026 Results

    Reports First Quarter 2026 Net Sales of $319 million Advances Turnaround Through Product and Brand Reset to Drive Sustainable Growth Continues Focus on Long-term Capital Structure Solutions, Including Strategic and Financing Options Sleep Number Corporation (NASDAQ:SNBR) today reported results for the quarter ended April 4, 2026. Linda Findley, President and CEO, commented, "Q1 came in as expected given the soft start to the year, but year-over-year demand improved steadily throughout the quarter, ending with growth in March over last year. We are confident in the early positive metrics we are seeing from our new product launch and marketing campaigns, and the customer feedback on o

    5/12/26 7:00:00 AM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    PROCEPT BioRobotics Reports First Quarter 2026 Financial Results

    SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2026. "Over the past six months, we have taken decisive actions to reset the organization by sharpening our focus on operational excellence, accountability, and commercial discipline, and our first quarter results reflect the early impact of that work," said Larry Wood, Chief Executive Officer. "We delivered $83.1 million in revenue, driven by strong U.S. system sales and improved pricing.

    4/29/26 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Sleep Number Announces Amendment to Credit Agreement

    Agreement with Existing Lenders Provides Additional $55 Million of Liquidity, Including a $25 Million Term Loan, and Relief on Certain Financial and Liquidity Covenants Company Remains Focused on New Product Rollout, New Marketing Campaign and Cost Management, while Evaluating Strategic Business Opportunities with its Advisors Performance Remains on Track with Company's 2026 First Quarter Expectations; Company to Announce First Quarter Results on May 12, 2026 Sleep Number (NASDAQ:SNBR) announced today that it has reached an agreement with its lenders that provides additional $55 million of liquidity, including a $25 million term loan, and relief on certain financial and liquidity cove

    4/28/26 8:00:00 AM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    $ISRG
    $PRCT
    $SNBR
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Sleep Number Corporation

    SC 13D/A - Sleep Number Corp (0000827187) (Subject)

    12/2/24 5:07:30 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Sleep Number Corporation

    SC 13D/A - Sleep Number Corp (0000827187) (Subject)

    11/25/24 6:54:27 PM ET
    $SNBR
    Home Furnishings
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/14/24 1:28:32 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care